A citation-based method for searching scientific literature

Charalampos Loutradis, Eirini Papadopoulou, Marietta Theodorakopoulou, Asterios Karagiannis, Pantelis Sarafidis. Future Med Chem 2019
Times Cited: 12







List of co-cited articles
90 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
66

SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA.
Pantelis Sarafidis, Charles J Ferro, Enrique Morales, Alberto Ortiz, Jolanta Malyszko, Radovan Hojs, Khaled Khazim, Robert Ekart, Jose Valdivielso, Denis Fouque,[...]. Nephrol Dial Transplant 2019
71
66

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
66

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
58

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
58

Sodium-glucose cotransporter-2 inhibitors and blood pressure decrease: a valuable effect of a novel antidiabetic class?
Konstantinos P Imprialos, Pantelis A Sarafidis, Asterios I Karagiannis. J Hypertens 2015
42
41

Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Melanie J Davies, David A D'Alessio, Judith Fradkin, Walter N Kernan, Chantal Mathieu, Geltrude Mingrone, Peter Rossing, Apostolos Tsapas, Deborah J Wexler, John B Buse. Diabetes Care 2018
41

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado,[...]. Lancet 2019
948
41

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
41

European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring.
Gianfranco Parati, George Stergiou, Eoin O'Brien, Roland Asmar, Lawrence Beilin, Grzegorz Bilo, Denis Clement, Alejandro de la Sierra, Peter de Leeuw, Eamon Dolan,[...]. J Hypertens 2014
473
33

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman. N Engl J Med 2016
25

Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis.
Despoina Vasilakou, Thomas Karagiannis, Eleni Athanasiadou, Maria Mainou, Aris Liakos, Eleni Bekiari, Maria Sarigianni, David R Matthews, Apostolos Tsapas. Ann Intern Med 2013
514
25

Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study.
Anna Solini, Livia Giannini, Marta Seghieri, Edoardo Vitolo, Stefano Taddei, Lorenzo Ghiadoni, Rosa Maria Bruno. Cardiovasc Diabetol 2017
145
25

The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus.
David Zi Cherney, Bruce A Perkins, Nima Soleymanlou, Ronnie Har, Nora Fagan, Odd Erik Johansen, Hans-Juergen Woerle, Maximilian von Eynatten, Uli C Broedl. Cardiovasc Diabetol 2014
298
25

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.
Francesco Cosentino, Peter J Grant, Victor Aboyans, Clifford J Bailey, Antonio Ceriello, Victoria Delgado, Massimo Federici, Gerasimos Filippatos, Diederick E Grobbee, Tina Birgitte Hansen,[...]. Eur Heart J 2020
856
25

CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Ele Ferrannini, Michael Mark, Eric Mayoux. Diabetes Care 2016
498
25

The optimal blood pressure target in diabetes mellitus: a quest coming to an end?
Eirini Papadopoulou, Elena Angeloudi, Spiridon Karras, Pantelis Sarafidis. J Hum Hypertens 2018
9
33

Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial.
Abhinav Sharma, Jennifer B Green, Allison Dunning, Yuliya Lokhnygina, Sana M Al-Khatib, Renato D Lopes, John B Buse, John M Lachin, Frans Van de Werf, Paul W Armstrong,[...]. Diabetes Care 2017
40
25

A comparison study of brachial blood pressure recorded with Spacelabs 90217A and Mobil-O-Graph NG devices under static and ambulatory conditions.
P A Sarafidis, A A Lazaridis, K P Imprialos, P I Georgianos, K A Avranas, A D Protogerou, M N Doumas, V G Athyros, A I Karagiannis. J Hum Hypertens 2016
22
25

Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial.
Anthony H Barnett, Ambrish Mithal, Jenny Manassie, Russell Jones, Henning Rattunde, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2014
345
16

Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.
Jackson T Wright, George Bakris, Tom Greene, Larry Y Agodoa, Lawrence J Appel, Jeanne Charleston, DeAnna Cheek, Janice G Douglas-Baltimore, Jennifer Gassman, Richard Glassock,[...]. JAMA 2002
16

Effects of Intensive BP Control in CKD.
Alfred K Cheung, Mahboob Rahman, David M Reboussin, Timothy E Craven, Tom Greene, Paul L Kimmel, William C Cushman, Amret T Hawfield, Karen C Johnson, Cora E Lewis,[...]. J Am Soc Nephrol 2017
173
16

Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis.
Dena Ettehad, Connor A Emdin, Amit Kiran, Simon G Anderson, Thomas Callender, Jonathan Emberson, John Chalmers, Anthony Rodgers, Kazem Rahimi. Lancet 2016
16


Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.
George L Bakris, Rajiv Agarwal, Juliana C Chan, Mark E Cooper, Ron T Gansevoort, Hermann Haller, Giuseppe Remuzzi, Peter Rossing, Roland E Schmieder, Christina Nowack,[...]. JAMA 2015
269
16

Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial.
George L Bakris, Rajiv Agarwal, Stefan D Anker, Bertram Pitt, Luis M Ruilope, Christina Nowack, Peter Kolkhof, Anna C Ferreira, Patrick Schloemer, Gerasimos Filippatos. Am J Nephrol 2019
43
16

2018 ESC/ESH Guidelines for the management of arterial hypertension.
Bryan Williams, Giuseppe Mancia, Wilko Spiering, Enrico Agabiti Rosei, Michel Azizi, Michel Burnier, Denis L Clement, Antonio Coca, Giovanni de Simone, Anna Dominiczak,[...]. Eur Heart J 2018
16

Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin.
David Z I Cherney, Mark E Cooper, Ilkka Tikkanen, Egon Pfarr, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Søren S Lund. Kidney Int 2018
87
16

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
B M Brenner, M E Cooper, D de Zeeuw, W F Keane, W E Mitch, H H Parving, G Remuzzi, S M Snapinn, Z Zhang, S Shahinfar. N Engl J Med 2001
16

Intensive blood-pressure control in hypertensive chronic kidney disease.
Lawrence J Appel, Jackson T Wright, Tom Greene, Lawrence Y Agodoa, Brad C Astor, George L Bakris, William H Cleveland, Jeanne Charleston, Gabriel Contreras, Marquetta L Faulkner,[...]. N Engl J Med 2010
446
16

A Randomized Trial of Intensive versus Standard Blood-Pressure Control.
Jackson T Wright, Jeff D Williamson, Paul K Whelton, Joni K Snyder, Kaycee M Sink, Michael V Rocco, David M Reboussin, Mahboob Rahman, Suzanne Oparil, Cora E Lewis,[...]. N Engl J Med 2015
16

Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis.
Pantelis A Sarafidis, Panagiotis C Stafylas, Aggeliki I Kanaki, Anastasios N Lasaridis. Am J Hypertens 2008
49
16

Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease: a systematic review and meta-analysis of randomized controlled trials.
Maria-Eleni Alexandrou, Aikaterini Papagianni, Apostolos Tsapas, Charalampos Loutradis, Afroditi Boutou, Alexia Piperidou, Dorothea Papadopoulou, Luis Ruilope, George Bakris, Pantelis Sarafidis. J Hypertens 2019
15
16


Effect of Blood Pressure Control on Long-Term Risk of End-Stage Renal Disease and Death Among Subgroups of Patients With Chronic Kidney Disease.
Elaine Ku, Mark J Sarnak, Robert Toto, Charles E McCulloch, Feng Lin, Miroslaw Smogorzewski, Chi-Yuan Hsu. J Am Heart Assoc 2019
10
20

Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial.
Luis M Ruilope, Rajiv Agarwal, Stefan D Anker, George L Bakris, Gerasimos Filippatos, Christina Nowack, Peter Kolkhof, Amer Joseph, Nicole Mentenich, Bertram Pitt. Am J Nephrol 2019
50
16

Prevalence, patterns of treatment, and control of hypertension in predialysis patients with chronic kidney disease.
Pantelis A Sarafidis, Claire C Sharpe, Eleri Wood, Rochelle Blacklock, Adam Rumjon, Aziza Al-Yassin, Rachel Ariyanayagam, Shanique Simmonds, Jessica Fletcher-Rogers, Katie Vinen. Nephron Clin Pract 2012
30
16

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
E J Lewis, L G Hunsicker, W R Clarke, T Berl, M A Pohl, J B Lewis, E Ritz, R C Atkins, R Rohde, I Raz. N Engl J Med 2001
16

Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections: A Population-Based Cohort Study.
Chintan V Dave, Sebastian Schneeweiss, Dae Kim, Michael Fralick, Angela Tong, Elisabetta Patorno. Ann Intern Med 2019
46
16

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study.
William G Herrington, David Preiss, Richard Haynes, Maximilian von Eynatten, Natalie Staplin, Sibylle J Hauske, Jyothis T George, Jennifer B Green, Martin J Landray, Colin Baigent,[...]. Clin Kidney J 2018
89
16

Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury.
Annayya R Aroor, Nitin A Das, Andrea J Carpenter, Javad Habibi, Guanghong Jia, Francisco I Ramirez-Perez, Luis Martinez-Lemus, Camila M Manrique-Acevedo, Melvin R Hayden, Cornel Duta,[...]. Cardiovasc Diabetol 2018
58
16


24-Hour Blood Pressure-Lowering Effect of an SGLT-2 Inhibitor in Patients with Diabetes and Uncontrolled Nocturnal Hypertension: Results from the Randomized, Placebo-Controlled SACRA Study.
Kazuomi Kario, Kenta Okada, Mitsutoshi Kato, Masafumi Nishizawa, Tetsuro Yoshida, Tsuguyoshi Asano, Kazuaki Uchiyama, Yawara Niijima, Tomohiro Katsuya, Hidenori Urata,[...]. Circulation 2018
75
16

Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes.
H J Lambers Heerspink, D de Zeeuw, L Wie, B Leslie, J List. Diabetes Obes Metab 2013
419
16


Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors.
T D Filippatos, V Tsimihodimos, M S Elisaf. Expert Opin Pharmacother 2016
23
16

Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF).
Jesper Jensen, Massar Omar, Caroline Kistorp, Mikael Kjær Poulsen, Christian Tuxen, Ida Gustafsson, Lars Køber, Finn Gustafsson, Emil Fosbøl, Niels Eske Bruun,[...]. Trials 2019
18
16

The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019).
Satoshi Umemura, Hisatomi Arima, Shuji Arima, Kei Asayama, Yasuaki Dohi, Yoshitaka Hirooka, Takeshi Horio, Satoshi Hoshide, Shunya Ikeda, Toshihiko Ishimitsu,[...]. Hypertens Res 2019
324
16

Renal Handling of Ketones in Response to Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 2 Diabetes.
Ele Ferrannini, Simona Baldi, Silvia Frascerra, Brenno Astiarraga, Elisabetta Barsotti, Aldo Clerico, Elza Muscelli. Diabetes Care 2017
74
16

Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin-angiotensin system blockade.
Michael A Weber, Traci A Mansfield, Federica Alessi, Nayyar Iqbal, Shamik Parikh, Agata Ptaszynska. Blood Press 2016
59
16


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.